FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1566907430> ?p ?o ?g. }

• W1566907430 endingPage "28" @default.
• W1566907430 startingPage "19" @default.
• W1566907430 abstract "We have previously shown that sorafenib, a multikinase inhibitor, exhibits cytotoxic effects on chronic lymphocytic leukemia (CLL) cells. Because the cellular microenvironment can protect CLL cells from drug-induced apoptosis, it is important to evaluate the effect of novel drugs in this context. Here we characterized the in vitro cytotoxic effects of sorafenib on CLL cells and the underlying mechanism in the presence of marrow stromal cells (MSCs) and nurselike cells (NLCs). One single dose of 10 µmol/L or the repeated addition of 1 µmol/L sorafenib caused caspase-dependent apoptosis and reduced levels of phosphorylated B-RAF, C-RAF, extracellular signal-regulated kinase (ERK), signal transducer and activator of transcription 3 (STAT3) and myeloid cell leukemia sequence 1 (Mcl-1) in CLL cells in the presence of the microenvironment. We show that the RAF/mitogen-activated protein kinase kinase (MEK)/ERK pathway can modulate Mcl-1 expression and contribute to CLL cell viability, thereby associating sorafenib cytotoxicity to its impact on RAF and Mcl-1. To evaluate if the other targets of sorafenib can affect CLL cell viability and contribute to sorafenib-mediated cytotoxicity, we tested the sensitivity of CLL cells to several kinase inhibitors specific for these targets. Our data show that RAF and vascular endothelial growth factor receptor (VEGFR) but not KIT, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) are critical for CLL cell viability. Taken together, our data suggest that sorafenib exerts its cytotoxic effect likely via inhibition of the VEGFR and RAF/MEK/ERK pathways, both of which can modulate Mcl-1 expression in CLL cells. Furthermore, sorafenib induced apoptosis of CLL cells from fludarabine refractory patients in the presence of NLCs or MSCs. Our results warrant further clinical exploration of sorafenib in CLL." @default.
• W1566907430 created "2016-06-24" @default.
• W1566907430 creator A5015043722 @default.
• W1566907430 creator A5036828560 @default.
• W1566907430 creator A5049841213 @default.
• W1566907430 creator A5050290780 @default.
• W1566907430 creator A5080851422 @default.
• W1566907430 creator A5083347752 @default.
• W1566907430 date "2011-10-04" @default.
• W1566907430 modified "2023-10-15" @default.
• W1566907430 title "Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1)" @default.
• W1566907430 cites W115619992 @default.
• W1566907430 cites W1492263161 @default.
• W1566907430 cites W1531083786 @default.
• W1566907430 cites W1534407869 @default.
• W1566907430 cites W1964899672 @default.
• W1566907430 cites W1966704219 @default.
• W1566907430 cites W1976767301 @default.
• W1566907430 cites W1976916701 @default.
• W1566907430 cites W1983565474 @default.
• W1566907430 cites W1987212294 @default.
• W1566907430 cites W1991233540 @default.
• W1566907430 cites W1996957538 @default.
• W1566907430 cites W1997533142 @default.
• W1566907430 cites W2008308389 @default.
• W1566907430 cites W2020485312 @default.
• W1566907430 cites W2023624246 @default.
• W1566907430 cites W2027723397 @default.
• W1566907430 cites W2036758696 @default.
• W1566907430 cites W2041230280 @default.
• W1566907430 cites W2043139965 @default.
• W1566907430 cites W2047964609 @default.
• W1566907430 cites W2055216141 @default.
• W1566907430 cites W2059299367 @default.
• W1566907430 cites W2060370107 @default.
• W1566907430 cites W2070396671 @default.
• W1566907430 cites W2075082022 @default.
• W1566907430 cites W2076479050 @default.
• W1566907430 cites W2090358449 @default.
• W1566907430 cites W2092759765 @default.
• W1566907430 cites W2093289553 @default.
• W1566907430 cites W2106478689 @default.
• W1566907430 cites W2124221273 @default.
• W1566907430 cites W2138178697 @default.
• W1566907430 cites W2140765540 @default.
• W1566907430 cites W2144785546 @default.
• W1566907430 cites W2151507583 @default.
• W1566907430 cites W2154992334 @default.
• W1566907430 cites W2166271687 @default.
• W1566907430 cites W2169093711 @default.
• W1566907430 doi "https://doi.org/10.2119/molmed.2011.00164" @default.
• W1566907430 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3269641" @default.
• W1566907430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21979753" @default.
• W1566907430 hasPublicationYear "2011" @default.
• W1566907430 type Work @default.
• W1566907430 sameAs 1566907430 @default.
• W1566907430 citedByCount "40" @default.
• W1566907430 countsByYear W15669074302012 @default.
• W1566907430 countsByYear W15669074302013 @default.
• W1566907430 countsByYear W15669074302014 @default.
• W1566907430 countsByYear W15669074302015 @default.
• W1566907430 countsByYear W15669074302016 @default.
• W1566907430 countsByYear W15669074302017 @default.
• W1566907430 countsByYear W15669074302018 @default.
• W1566907430 countsByYear W15669074302019 @default.
• W1566907430 countsByYear W15669074302020 @default.
• W1566907430 countsByYear W15669074302021 @default.
• W1566907430 countsByYear W15669074302022 @default.
• W1566907430 crossrefType "journal-article" @default.
• W1566907430 hasAuthorship W1566907430A5015043722 @default.
• W1566907430 hasAuthorship W1566907430A5036828560 @default.
• W1566907430 hasAuthorship W1566907430A5049841213 @default.
• W1566907430 hasAuthorship W1566907430A5050290780 @default.
• W1566907430 hasAuthorship W1566907430A5080851422 @default.
• W1566907430 hasAuthorship W1566907430A5083347752 @default.
• W1566907430 hasBestOaLocation W15669074301 @default.
• W1566907430 hasConcept C121608353 @default.
• W1566907430 hasConcept C126322002 @default.
• W1566907430 hasConcept C154317977 @default.
• W1566907430 hasConcept C184235292 @default.
• W1566907430 hasConcept C185592680 @default.
• W1566907430 hasConcept C202751555 @default.
• W1566907430 hasConcept C203014093 @default.
• W1566907430 hasConcept C2777938653 @default.
• W1566907430 hasConcept C2778019345 @default.
• W1566907430 hasConcept C2778461978 @default.
• W1566907430 hasConcept C2778695046 @default.
• W1566907430 hasConcept C2778729363 @default.
• W1566907430 hasConcept C2778820342 @default.
• W1566907430 hasConcept C42362537 @default.
• W1566907430 hasConcept C502942594 @default.
• W1566907430 hasConcept C55493867 @default.
• W1566907430 hasConcept C57074206 @default.
• W1566907430 hasConcept C62478195 @default.
• W1566907430 hasConcept C71924100 @default.
• W1566907430 hasConcept C86803240 @default.
• W1566907430 hasConcept C95444343 @default.
• W1566907430 hasConceptScore W1566907430C121608353 @default.

• next